Prophylactic atropine administration attenuates the prolongation induction time of prior administration of remifentanil.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003179

Enrollment

Registered

2018-09-12

Start date

2018-09-12

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The study participants were randomly assigned to two groups: Remifentanil and Atropine 0.5 mg (Group A) and Remifentanil only (Group N). In the N group without the administration of atropine, t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) adult patients of American Society of Anaesthesiologists physical status class I and II (19-75 years) 2) Patients undergoing general anesthesia and undergoing arterial blood pressure monitoring

Exclusion criteria

Exclusion criteria: 1) Children (under 19 years old) 2) BMI> 30 kg / m 2 or <18.5 kg / m 2 3) Neuromuscular disease or mental illness 4) patients with Metabolic disease 5 )Patients who are expected to have a difficile airway. 6) Patients diagnosed with asthma or Chronic obstructive pulmonary disease 7) Patients with Cardiovascular disease (including hypertension) 8) Patients with renal disease

Design outcomes

Primary

Measure	Time frame
induction time	—

Secondary

Measure	Time frame
Time difference between loss of consciousness;Changes in vital sign and BIS within induction period	—

Countries

Korea, Republic of

Contacts

Public ContactJin Hee Ahn

Samsung Medical Center

blattblatt@naver.com+82-2-3410-2470

Outcome results